Myriad Pharmaceuticals Inc. to Present at the 21st Annual Piper Jaffray Health Care...

Myriad Pharmaceuticals Inc. to Present at the 21st Annual Piper Jaffray Health
Care Conference

SALT LAKE CITY, Nov. 23, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc.
(Nasdaq:MYRX) announced today that Adrian Hobden, President and CEO, is
scheduled to present an overview of the Company at the 21st Annual Piper Jaffray
Health Care Conference, at 10:00 a.m. Eastern on December 1, 2009, at the New
York Palace Hotel in New York City.

The presentation will be available via live audio webcast on the Company's
website at www.myriadpharma.com. An archived replay will also be located on the
Company's site following the event.

About Myriad Pharmaceuticals

Myriad Pharmaceuticals, Inc. is a pharmaceutical company focused on discovering,
developing, and commercializing novel small molecule drugs that address severe
medical conditions, including cancer and HIV infection. Our pipeline includes
clinical and pre-clinical product candidates with distinct mechanisms of action
and novel chemical structures that have the potential to be first-in-class
and/or best-in-class therapeutics. For more information visit
www.myriadpharma.com.

The Myriad Pharmaceuticals, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=6327

This press release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995, including statements
relating to the scheduled presentation of an overview of the Company at the
Piper Jaffray Conference on December 1, 2009. These "forward-looking statements"
are based on management's current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by forward-looking
statements. These risks and uncertainties include, but are not limited to: the
risk that we may be unable to further identify, develop and achieve commercial
success for new products and technologies; the risk that we may be unable to
discover drugs that are safer and more efficacious than our competitors; the
risk that we may be unable to develop and maintain manufacturing capabilities
for our products; the possibility of delays in the research and development
necessary to select drug development candidates and delays in clinical trials;
the risk that clinical trials may not result in marketable products; the risk
that we may be unable to successfully finance and secure regulatory approval of
and market our drug candidates, or that clinical trials will not be completed on
the timelines we have estimated; uncertainties about our ability to obtain new
corporate collaborations and acquire new technologies on satisfactory terms, if
at all; the development of competing products and services; the risk that we may
be unable to protect our proprietary technologies; the risk of
patent-infringement claims; risks of new, changing and competitive technologies
and regulations in the United States and internationally; and other factors
discussed under the heading "Risk Factors" " in our Annual Report on Form 10-K
for the year ended June 30, 2009, which has been filed with the Securities and
Exchange Commission, as well as any updates to those risk factors filed from
time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form
8-K.. All information in this press release is as of the date of the release,
and Myriad Pharmaceuticals undertakes no duty to update this information unless
required by law.

-0-
CONTACT: Myriad Pharmaceuticals, Inc.
Patrick M. Burke, Ph.D.,
V.P. Corporate and Business Development
801-214-7822
investor.relations@myriadpharma.com